Introduction: To examine the current literature regarding the clinical application of adipose-derived stem cells (ADSCs) for the management of orthopaedic pathologies
Introduction
Stromal cells can be obtained from the extracellular matrix of adipose tissue, bone marrow, synovial membranes, dental pulp, tendons, bone and periosteum trabeculae, skeletal muscle, nervous system, skin and placenta. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] These cells appear to be similar in morphology and function to mesenchymal bone marrow cells, and have essentially an immunophenotype compatible with the definition of mesenchymal stem cells (MSCs), although with variation depending on the tissue of origin, method of isolation and type of culture. 9, 12, [16] [17] [18] These cells have been isolated and cultured, and their characteristics have been tested. The available scientific literature gives no description of the characteristics and behaviour of adipose-derived stem cells (ADSCs) in uncontrolled and not manipulated conditions. 16, 19, 20 The stemness characteristics, the immunomodulatory properties and the wide distribution in adults have shown MSCs as an important application for regenerative medicine and research. For these purposes, many aspects need to be considered, from the collection of adipose tissue to the method of isolation of stromal portion and subsequent culturing. These procedures impact not only on the characteristics of the cells, but also on their viability and survival after cryopreservation, and may affect the repeatability of the experimental data. 16 In general, the ideal type of MSC should be easily isolated in large amounts, should maintain the characteristics of stem cell, and should consist of minimally manipulated cells both during the phase of isolation and in vitro, in case of therapeutic applications. [21] [22] [23] Classically, MSCs can be obtained from the stromal fraction of bone marrow (HBM-MSC). [2] [3] [4] 24, 25 HBM-MSC present several limiting features. Harvesting involves the surgical removal of the matrix portion; this is subsequently disintegrated by mechanical stress. This process allows to isolate from 0.01% to 0.001% of mononuclear cells from the harvested cells. 9, 26 In addition to the low availability and the invasive method, the use of HBMMSCs has been associated with viral infections that alter the clonogenic characteristics. 24, 25, 27, 28 Also, HBM-MSCs harvested from aged donors show a decrease in their differentiation potential. 26, 29 For these reasons, new sources of mesenchymal cells have been considered to satisfy the requirements of easy availability and stability of the cells. [3] [4] [5] 22, 26 Among these, the stromal fraction of adipose tissue is a reliable source of MSC. MSCs harvested from adipose tissue (ADSCs) together with the HBM-MSC are widely studied. 30 ADSCs show properties and characteristics equivalent to multipotent cells isolated from other tissues such as bone marrow. 31, 32 In addition, these stromal cells are able to differentiate into several cellular lines including, adipocytes, chondrocytes, osteoblasts, hepatocytes, pancreatic cells, muscle cells and neurons like cells both in vitro and in vivo. 15, 31, [33] [34] [35] [36] [37] [38] The most promising aspect of ADSCs lies in their location: adipose tissue is distributed in each region of the body, and represents 10-30% of the weight of a healthy person, with an isolation yield of 5000 cells per gram of tissue. Furthermore, in surgical liposuction procedures 30 ml-6 l of lipoaspirate are removed and would normally be discarded. 21, 26 A limiting factor in the clinical application of ADSCs is the manipulation during laboratory procedures: the lipoaspirate, which contains, in addition to ADSCs, aggregates of adipocytes, collagen fibres, blood and vascular components, is processed enzymatically with collagenase A type I, and undergoes haemolysis before culturing. Despite the promising results reported, both in regenerative and reconstructive medicine, there are still many challenges to overcome to introduce ADSCs in routine clinical practice, especially in regards to isolation, indications and safety. [39] [40] [41] [42] This systematic review evaluates the current application in literature of ADSCs in humans for orthopaedic ailments, and assesses the efficacy, tollerability, safety and future development in vivo for the management of orthopaedic conditions. April 14, 2017) were searched by two independent reviewers for clinical application of ADSCs in musculoskeletal medicine. This metaanalysis was conducted on the basis of the Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA) guidelines (Fig. 1) . 43 The search terms used were 'adipose stem cells' OR 'adipose mesenchymal stem cells' OR 'stromal vascular fraction' OR 'adipose-derived stem cells' AND ['ortho-
Materials and methods

MEDLINE, SCOPUS, CINAHL and EMBASE (1950 to
Initially, the search led to evaluate a total of 8459 articles; after initial assessment, a total of 537 articles remained. Of these, 514 were subsequently excluded based on the search criteria. Finally, 23 studies met the inclusion criteria and were included in the study. Inclusion and exclusion criteria
In this review, we included study of Levels I, II, III and IV regarding human subjects, with no age restriction, treated with ADSC. The assessment of level of evidence of the selected articles was performed according to 'The Oxford 2011 Levels of Evidence'. 67 Morever no follow-up limit was required as inclusion or exclusion criteria. We excluded from the study reviews, meta-analyses, expert opinions, case reports, case series with less than five patients, animal studies, in vitro studies and editorials. Two independent reviewers analysed and evaluated all the information available from the articles. In cases of disagreement between the two reviewers, a third senior reviewer was asked to evaluate and analyse the articles.
Results
The details of the 23 articles included in the present systematic review are reported in Table 1 . 45, 46, [55] [56] [57] [58] 62, 64, 65 , one article (4.35%) dealt with bone defect, 44 while one (4.35%) article evaluated the safety related to the treatment of joint disease. 63 Altogether, 1746 procedures were considered; all investigations were published between 2012 and 2017. The total number of complications identified in the present review is 254/1746 (14.55%), most of which were minor, such as joint pain or other complications not directly related to the treatment. Four studies (17.39%) used ADSCs in combination with PRP. 56, 60, 63, 65 For what concerns clinical applications, six studies (26.0%) used a direct intra-or peri-articular or intra-or peritendinous; 15 studies (65.3%) used ADSCs during surgical procedure, while in the remaining two (8.7%) injections were performed on the same day of the arthroscopy after stem cell preparation (3-4 h).
Osteochondral lesions
Kim et al. in 2015 treated 54 patients (56 knees) with symptomatic knee OA using ADSCs, harvested from the patient's buttock. 49 Patients were divided into two groups:
-ADSCs implantation without a scaffold (Group 1 -39 knees) -ADSCs loaded in fibrin glue scaffold (Group 2 -17 knees)
Both groups showed significant clinical improvement (IKDC and Tegner score). Nine lesions in Group I (23%) and 12 (58%) in Group 2 reached a grade of I or II using the ICRS classification. In Group I, being overweight and having a larger size of the lesion were significant negative predictive factors.
The same investigators compared the results of two groups of patients undergoing different treatment with ADSCs harvested from the patient's buttock:
-ADSCs injection in association with PRP (injection group; n = 20) -ADSCs implantation on a fibrin glue scaffold (implantation group; n = 20) 51 Second-look arthroscopy, performed more than 1 year after the index treatment, showed significant improvement in IKDC and Tegner activity. Moreover, at final follow-up (28.6 months postoperatively), IKDC and Tegner activity scores showed a further improvement in the implantation group, with a higher IKDC in the implantation group. The ICRS grades were significantly higher in the implantation group. Kim et al. investigated patients with symptomatic knee OA who underwent implantation of ADSCs harvested from the buttocks. 47 At final follw up, 26 patients (65%) in Group 1 showed a complete cartilage coverage of the lesion, while in Group 2 this happened in 18 patients (45%). The MOCART score was significantly higher in Group 1 compared to Group 2 patients. Clinical follow-up at 27.4 months showed higher KOOS in Group 1 than in Group 2. Second-look arthroscopy, performed in 57 knees (30 in Group 1 and 27 in Group 2), highlighted good repair tissue quality with no differences between the two groups.
Kim et al. treated arthroscopically 65 elderly patients (>50 years) for ostechondral lesion of the talus (OLT), dividing them into two groups:
-isolated marrow stimulation (Group A -37 ankles) and -marrow stimulation in association with ADSC harvested from the buttock (Group B -31 ankles) 54 At final follow-up, patients in Group B showed greater clinical improvements compared to those in Group A, especially in lesions greater than 109 mm 2 . The same group compared imaging results in 49 patients (50 ankles) who underwent arthroscopic treatment for symptomatic OLTs. 52 Patients were divided in two groups:
-marrow stimulation alone (conventional group -26 ankles), -marrow stimulation in association with ADSCs injection, harvested 1 day before arthroscopic surgery from the patient's buttock (ADSCs group -24 ankles).
At final follow-up, the ADSCs group showed higher clinical (American Orthopeadic Foot and Ankle Score (AOFAS), and Tegner scores) and imaging (MOCART) scores, with a significant association between MOCART and clinical scores in both groups. Age, lesion size and the presence of subchondral cysts were correlated with a lower MOCART score in the conventional group but not in the ADSCs group.
Tendinopathy
In 2015, Lee et -23 patients received only PRP injection, and -21 underwent ADSCs therapy plus PRP injection. 60 All patients underwent a second-look arthroscopy at the moment of removal of the fixation devices, revealing fibrocartilage coverage of the lesion in 50% of the ADSCs-PRP group patients, and only 10% in the other group. The ADSCs-PRP group reported significant greater improvements in all clinical scores compared to the PRP-only group, except for the mean Lysholm score. Imaging parameters (femorotibial angles and weight-bearing lines) did not show any pre-or post-operative differences between the two groups.
Kim et al. assessed 49 patients with ankle osteoarthritis and varus deformity treated with arthroscopic marrow stimulation and lateral sliding calcaneal osteotomy: 23 ankles underwent marrow stimulation alone (Group 1), and 26 underwent marrow stimulation in association with ADSCs injection derived from the fat pad harvested from their buttock (Group 2). 50 Second-look arthroscopy more than 1 year after surgery evidenced a higher ICRS score in Group 2 patients. At the latest follow-up, clinical outcomes (VAS, AOFAS) had improved significantly in all patients, and were significantly higher in Group 2 patients. Recently, Kim et al. reported clinical and imaging results in two different groups of patients who had undergone supramalleolar osteotomy and second-look arthroscopy:
-bone marrow stimulation alone (Group I -33 patients). -bone marrow stimulation plus ADSCs injection (harvested from both buttocks) (Group II -31 patients).
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Both groups reported significant improvement in VAS and AOFAS scores; moreover, Group II showed a significant higher AOFAS and lower VAS at the final follow-up. Second-look arthroscopy revealed a better ICRS grade in Group II.
Osteoarthritis
Fodor et al. treated six patients with symptomatic osteoarthritis (OA) of the knee (Grade I-III of the Kellgren-Lawrance scale) using a direct injection of autologous ADSCs harvested from the abdomen, flanks, and/or lateral thigh. 45 No adverse events such as infections or pain were recorded. At 3 months, all patients reported clinical improvements maintained up to 1 year. All patients resumed normal activities of daily living with decreased knee pain. Recently, Pers et al. assessed the effect of a an intra-articular injection of ADSCs, obtained by liposuction under local anaesthesia in 18 patients with knee OA. 64 Three patient cohorts, each consisting of six patients, were treated with infiltration at increasing cell amounts:
-low dose (2 × 10 6 cells),
-medium dose (10 × 10 6 cells), and -high dose (50 × 10 6 cells).
Six months after the injection, no adverse events were reported. Only four patients reported transient knee discomfort immediately after the injection. Of the three cohorts, the low-dose group reported significant improvements in pain relief.
Jo et al. evaluated clinical outcomes of intraarticular injection of autologous ADSCs, harvested from the abdominal subcutaneous fat by liposuction, for knee OA in 18 patients. 46 The study protocol consisted of two phases: -Phase I: three cohorts of three patients each with increasing dose (low, mid and high). -Phase II: one cohort of nine patients all treated with high dose.
No complications were reported. In the high-dose group, the WOMAC score showed significant improvement 6 months after treatment; moreover, arthroscopy revealed a reduction of the size of the lesion with an increase of the cartilage, confirmed at histology to have the appearance of regenerated hyaline cartilage.
Koh et al. assessed the efficacy of ADSCs injection harvested from the infrapatellar fat pad for the treatment of 25 knee OA. 57 Each patients underwent arthroscopic debridement in association with ADSCs injection. At the end of the observation period, all patients showed significant clinical improvements (Lysholm, Tegner and VAS) with no adverse effects. The same group evaluated the outcomes of 18 patients who underwent intra-articular injections of autologous ADSCs, harvested from the inner aspect of the infrapatellar fat pad, for symptomatic knee OA. 58 ADSCs in association with 3.0 ml of PRP were injected directly into the joints. WOMAC, VAS and Lysholm scores improved significantly at the final follow-up. MRI showed an improvement in the cartilage whole-organ MRI score. Koh et al. investigated the effect of ADSCs, harvested 1 day before arthroscopy, from the patients' buttocks through tumescent liposuction. 55 Moreover, the authors investigated the predictive factors in outcome of treatment with ADSCs. After ADSCs implantation for cartilage defect, 37 patients underwent second-look arthroscopy, performed at a mean follow-up of 26.5 months. According to the ICRS classification, two (5%) lesions were classified as Grade I, seven (19%) as Grade II, 20 (54%) as Grade III, and eight (22%) as Grade IV. Almost all patients (94%) were satisfied with the operation. All patients were re-evaluated at 6, 12 and 18 months after treatment. The treatment group showed significantly differences compared with the Placebo group in WOMAC, VAS and Lysholm scores. Outerbridge classification, measured with MRI, showed non-differences between the two group, but Outerbridge score scores increased in the placebo group over time, but decreased in the treatment group. No adverse events reletad to the treatment were recorded in either group.
Michalek et al. in 2015 evaluated 1128 patients (1856 joints), at a mean follow-up of 17.2 months, with Grade 2-4 degenerative OA treated with a single injection of freshly isolated autologous ADSCs. 62 ADSCs, obtained after standard liposuction, were isolated and prepared for application into one to four major joints. No serious side effects were reported throughout the follow-up. Significant improvement was reported between 3 and 12 months after treatment. Almost all patients (91%) reported an improvement of at least 50% of the clinical score at 1 year after treatment.
Bone defects
Dufran et al. treated six patients with severe bone loss using a human autologous scaffold-free osteogenic 3-dimensional (3D) graft derived from autologous ADSCs. 44 The final product obtained was stable and resistant, and easy to implant directly into the bone defect. The scaffold was used to treat three bone cancer and three patients with pseudarthrosis. No adverse effects were reported 4 years after implantation.
Safety
At a mean of almost three years, 91 patients treated with autologous ADSCs, harvested from the patient's abdomen using a tumescent solution, in association with PRP for different orthopaedic conditions were assessed. 63 ADSCs in association with PRP were injected into various joints (n = 100). VAS showed improvement after 1 month of follow-up (6.55), with further improvement at the final follow-up of 3 months (4.43). Minor self-limited complications such as swelling, tenosynovitis and tendinopathy were reported by most elderly patients; no complications related to tumour or cancer were detected.
Discussion
This systematic review evaluated the current literature on the clinical application of ADSCs in humans in a orthopaedic pathologies to assess the efficacy, tolerability, safety and possible future developments for the management of several orthopaedic conditions. Clinical trials which evaluate the effect of ADSCs can be considered a choice of treatment in addition to other widely studied regenerative medicine procedures such as bone marrow mesenchymal stem cells injections. The main reasons for which the ADSCs have been the subject of numerous clinical and pre-clinical studies in recent years is attributable to their high number in the human body (ADSCs are 5% of nucleated cells in adipose tissue), the simplicity of harvesting with a lower donor-site morbidity, and their rapid expansion and high proliferative potential.
Moreover, ADSCs are able to maintain their own features even if manipulated through different cultures compared to other cellular lines. 31, 68, 69 ADSCs are easily obtained from adipose tissue under the skin.
Several techniques have been reported for fat harvesting, such as Coleman's technique, liposuction and direct excision of the fat, all aiming to improve the quality and quantity of ADSCs. 70 Currently, Coleman's technique is the most popular, and was first described in 1994. 71 Liposuction techniques include conventional liposuction (tumescent) and ultrasound-assisted liposuction. 72, 73 Tumescent liposuction is undertaken after injection of Klein's solution into the subcutaneous tissue, followed by suction-assisted aspiration of ADSCs using a microcannula. Ultrasound-assisted liposuction was designed to injury subcutaneous adipose tissue and to ease the harvesting process. 73 Adipose tissue is largely represented, and the area of fat harvesting influences the stem cell yield. 68 Normally, adipose tissue can be harvested from the belly or the hip/thigh region. [73] [74] [75] Patient's age can affect ADSCs yield. All age groups present similar ADSCs and osteogenic paracrine activities. 20, 24, 76 In contrast, ADSCs from newborns present higher angiogenic and osteogenic capabilities than those from adults. Proliferative activity, colony-differential potential, and population doubling differ between young adults (>20 years old) and more elderly subjects (50-70 years old). 77 Only in one study were allogeneic cells used. 61 In the study of Lee et al. allo-ADSCs were obtained and processed from healthy donors, prior informed consent, and were then injected under ultrasound guidance. Further studies will be conducted on the benefits of allotransplant, as this procedure blends the ease in handling harvested cells with standardization of the process. Moreover, the liposuction and processing step would be eliminated, reducing surgical time, and a pre-selection of healthy donors, according to their cytokine and cellular lines, could improve the treatment with ADSCs. 78 In all the other studies, ADSCs were obtained from autologous subcutaneous adipose tissue from the buttocks or retropatellar fat.
Almost all studies (82.6%) regards knee or ankle disorders, [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [64] [65] [66] in particular to treat cartilage defect or osteoarthritis [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] 64, 65 : if ADSCs are cultured in high density culture in association with transforming growth factor beta (TGFb), growth hormone and fibroblast growth factor-2 (FGF-2), and located in a fibrin glue scaffold placed into the lesion, they have the potential to form tissue with hyaline cartilage phenotype. 79 Only two studies used the ADSCs in the management of tendinopathy. 61 This process leads to the formation of normal bone components, such as calcium phosphate, osteocalcin, and collagen type I, and are also stimulated genes that promote bone formation (Run2 and Osterix). Furthermore, FGF2 is another factor that enhance osteogenesis if added to MSC. 84 Once these stem cells have differed into osteoblasts, are able to produce proteins typical of the bone osteoblastic cellular line. ADSCs seem to produce excellent clinical results, although with different follow-up in the treatment of various diseases. In fact, all the studies report subjective and objective clinical improvements with minimal complication rates. Analysing the complications rates on 1746 patients treated with mesenchymal cells of adipose origin, none suffered serious complications, and none developed a tumour. The total number of complications identified in the present review is 254/1746 (14.55%), most of which were minor, such as joint pain or other complications not directly related to the treatment.
There are several ways to deliver ADSCs to diseased or injured tissues. The systemic delivery of ADSCs is dependent on the 'native' homing of ADSCs to the injured site. On their surface ADSCs express different receptors for cytokine and chemokine which helps them to be recruited to the suffering areas thanks to a chemotactic gradient secreted from the same injured tissue. Among the included studies, it is also possible to observe a difference in the delivery way of ADSCs: in six studies ADSCs (26.0%) were used by direct intra-or peri-articular or tendinous injection to the injuried site; in 15 studies (65.3%) ADSCs were applied during surgery, and in the remaining two (8.7%) injection of the ADSCs was performed the same day of the arthroscopy after stem cell preparations (3-4 h) .
Intra-articular injection of ADSCs can lead to a significant improvement of the cartilage and subchondral bone, protecting against arthritic processes, regardless of the source of harvesting. 85 On the other hand, scaffolds may affect the proliferation and differentiation of stem cells by controlling chemical compositions and physical properties. The ideal scaffold should stimulate cell attachment, growth and differentiation, as well as the formation and organization of new tissue. Scaffolds can be permanent, in this case with the purpose of ensuring a reliable support for cells andnew-tissue, or temporary as a means of cell delivery system. 80, 81, 86 Furthermore, in some studies ADSCs have been used in combination with PRP 56, 60, 63, 65 coadministration of ADSCs and other chemical components can enhance the effect, allowing to use a smaller amount of drugs or devices and possibly decreasing adverse effects. [87] [88] [89] [90] [91] Tumours release of a number of chemical signals such as cytokines, which recruit ADSCs, enabling ADSCs as transporter for cancer drugs; moreover, ADSCs could have a carcinogenic effect promoting angiogenesis and improving the tumour environment. [92] [93] None of the studies identified is a randomized double-blinded trial, and most of the selected studies present major limitations, and different methods, counfounding the results of our review.
First of all, in many studies ADSCs were in association with PRP. In this case, it is not possibile to establish the effects of ADSCs alone from those of PRP. Furthermore, the association with surgical procedures, such as debridement, can lead to clinically relevant improvement as regards pain in the short term. Finally, the lack of a control to confirm the efficacy of ADSCs in orthopeadic conditions.
Conclusions
Although the literature is scarce regarding the use of ADSCs in humans for orthopaedic pathologies, preliminary outcomes are very encouraging, with a low rate of complications. Different delivery systems for these stem cells are being tested. ADSCs can be administered either with a simple injection or during surgical procedure. Clinical research regarding the use of ADSCs is very limited and, at present, long-term safety is the biggest challenge of ADSCs based regenerative medicine. It is necessary to conduct more and better studies to ascertain whether ADSCs really play a role in modern orthopaedic surgery.
